TLR1 and neoplasm: In mouse tumor models, research has demonstrated that adding adjuvants such as PAM3CSK4, a TLR2 and TLR1 agonist, to LNPs enhances humoral immunity, cellular responses, tumor inhibition, and survival rates (52).